

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Skadden, Arps, Slate, Meagher & Flom LLP			
2. Address <input type="checkbox"/> Check if different than previously reported 1440 New York Avenue, N.W. Washington, D.C. 20005			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country): _____			
4. Contact Name James A. Losey	Telephone (202) 371-7000	E-mail (optional)	5. Senate ID # 35560-191
7. Client Name <input type="checkbox"/> Self Glaxo Wellcome, Inc.	6. House ID # 31706025		

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ → Termination Date _____

11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> → \$ <u>20,000</u> Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> → \$ _____ Expenses (nearest \$20,000)
14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
<input type="checkbox"/> Method A. Reporting amounts using LDA definitions only	
<input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code	
<input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code	

Signature _____

Printed Name and Title

JAMES A. LOSEY, PARTNER

FD-2 (REV. 6/98)

PAGE 1 of 4

Registrant Name Skadden, Arps Client Name Glaxo Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Efforts regarding U.S. government position on the Montreal Protocol "transition strategy" for the Metered-dose inhalers, as well as national regulatory actions regarding same issue.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House of Representatives
U.S. Senate
Environmental Protection Agency
Department of State

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
James A. Losey, Partner		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.

Signature _____ Date _____

Printed Name and Title _____

Registrant Name Skadden, Arps Client Name Glaxo Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENV (one per page)

16. Specific lobbying issues

Efforts regarding US government position on the Montreal Protocol "transition strategy" for the metered-dose inhalers, as well as national regulatory actions regarding same issue.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

U.S. House of Representatives
U.S. Senate
Environmental Protection Agency
Department of State

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
James A. Losey, Partner		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None

Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC, sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patient and physician access to essential medical treatment options.

Signature James A. Losey Date 8/13/99

Printed Name and Title James A. Losey, Partner

Form L.D-2 (Rev. 6/96)

Page 3 of 4

Registrant Name Skadden, Arps Client Name Glaxo Wellcome, Inc.

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

Robert E. Lighthizer

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

Signature _____ Date _____

Printed Name and Title _____

Form LD-2 (Rev. 6/98)

Page 4 of 4